Perioperative Treatment Outcomes of Early NSCLC

N/AEnrolling By InvitationNCT06610240

Shanghai Chest Hospital500 enrolled

Overview

This is an observational study evaluating the clinical characteristics, treatment patterns, and clinical outcomes of perioperative NSCLC patients receiving different treatment strategies. According to the inclusion and exclusion criteria, perioperative NSCLC patients admitted to the study center from January 1, 2020, to one year after the study initiation will be retrospectively screened and collected.

Study Type

OBSERVATIONAL

Enrollment

500

Conditions

NSCLC

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Stage I-III NSCLC patients confirmed by histological or cytological examination based on the 8th edition of the AJCC staging system. * Patients who have undergone radical lung cancer surgery. * Patients who have received neoadjuvant treatment before radical lung cancer surgery, including chemotherapy, targeted therapy, or immunotherapy both alone or combined. Exclusion Criteria: * Patients with other previous malignancies, except those who achieved complete remission at least two years before radical lung cancer surgery and did not require additional treatment. * Patients with incomplete key baseline and treatment information，including clinical stage, pathological type, neoadjuvant treatment, pathological response, imaging response after neoadjuvant. * Patients included in anti-tumor drug intervention or unblinded clinical trials, in which the treatment being administered is unknown. * Prior surgery, radiotherapy or systemic therapy for NSCLC, including radiofrequency ablation, etc.

Locations (1)

Zhong Hua

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

event-free survival

the time from randomization to any progression of disease precluding surgery, progression or recurrence of disease after surgery, progression of disease in the absence of surgery, or death from any cause;

Time frame: From date of diagnosis until the date of first documented progression, recurrence or date of death from any cause, whichever came first, assessed up to 36 months

overall survival

from diagnosis to death

Time frame: From date of diagnosis until the date of death from any cause, whichever came first, assessed up to 60 months

Secondary Outcomes

R0 resection rate

margin negative resection

Time frame: usually 1 week after surgery

major pathological response

viable tumor cell less than 10%

Time frame: usually 1 week after surgery

p-CR

no viable tumor cells was observed

Time frame: usually 1 week after surgery

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.